JASMINE SPEARMAN: Open Payments
NPI 1477215168 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,147 in 100 payments from 31 companies in 2025. Trend: 2023 $4,490 · 2024 $3,650 · 2025 $2,147
Food & beverage: $2,052Education: $95
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 13 | $304 |
| Novartis Pharmaceuticals Corporation | 13 | $258 |
| Gilead Sciences, Inc. | 8 | $242 |
| PFIZER INC. | 6 | $114 |
| ABBVIE INC. | 5 | $105 |
| GlaxoSmithKline, LLC. | 5 | $102 |
| Merck Sharp & Dohme LLC | 4 | $95 |
| AstraZeneca Pharmaceuticals LP | 4 | $89 |
| Janssen Biotech, Inc. | 5 | $89 |
| Stemline Therapeutics Inc. | 5 | $88 |
Products named: Enhertu, Trodelvy, KISQALI, JEMPERLI, Orserdu, REBLOZYL, LIBTAYO, ELAHERE.
Industry payments across LA — which companies pay providers there.
